Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Posoleucel (ALVR105) for Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
2020-000722-26Phase 3Terminated
- Sponsor
- AlloVir, Inc.
- Start
- Sep 2020
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hemorrhagic cystitis (HC) and BK polyomavirus infection comparing Posoleucel with Placebo (2 arms). Primary endpoint: Time to resolution of macroscopic hematuria. Started Sep 2020; status: terminated.
02
Drugs
posoleucel
03
Conditions
hemorrhagic cystitis (HC)BK polyomavirus infection
Beyond the preview
Go deeper on 2020-000722-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000722-26.